Fountain, California Clinical Trials

A listing of Fountain, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

mini-mental state examination
florbetapir
flortaucipir
alzheimer's disease
positron emission tomography
Irvine Clinical Research Center
 (7.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +85 other locations
NA-831 Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

electrocardiogram (ecg)
SARS
critical illness
dexamethasone
complete blood count
Coronavirus Research Institute
 (7.0 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +29 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
haemophilia a
antihemophilic factor
severe haemophilia a
fitusiran
Investigational Site Number 8400010
 (7.0 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +10 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

haemophilia a
antihemophilic factor
severe haemophilia a
fitusiran
hemophilia
Investigational Site Number 8400016
 (7.0 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +40 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
haemophilia a
antihemophilic factor
severe haemophilia a
fitusiran
Investigational Site Number 8400010
 (7.0 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +5 other locations
test v6.10  

test

Orange County Research Center
 (8.3 away)
  • 0 views
  • 02 Aug, 2023
  • +1 other locations
None

Center for Inherited Blood Disorders (CIBD)-Site Number:8400001
 (7.0 away) Contact site
  • 0 views
  • 26 Sep, 2023
  • +2 other locations
BCI-FES Therapy for Stroke Rehabilitation

There are over 7 million stroke survivors in the US alone, with approximately 795,000 new cases annually. Despite the best available physiotherapy, 30-60% of stroke survivors remain affected by difficulty walking, with foot weakness often being the main cause. Given that post-stroke gait impairments remain poorly addressed, new methods that …

intracranial hemorrhage
stroke
foot drop
ischemic stroke
weakness
University of California, Irvine - Sue & Bill Gross Stem Cell Research Center
 (7.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of AK104 a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

cancer treatment
metastatic cervical carcinoma
adenosquamous carcinoma
cervical carcinoma
immunosuppressive
Womens Cancer Research Foundation
 (6.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +19 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

testosterone
antiandrogens
prostate cancer
prostatic neoplasms, castration-resistant
enzalutamide
The University of California, Irvine Medical Center
 (7.0 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations